Structures of staurosporine bound to CDK2 and cAPK - New tools for structure-based design of protein kinase inhibitors

Structure

Volumn 5, Issue 12, 1997, Pages 1551-1556

  Toledo, Leticia M ^a   Lydon, Nicholas B ^a  

^a Kinetix Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031574375     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(97)00304-3     Document Type: Review

References (31)

1. Ullrich, A. & Schlessinger, J. (1990). Signal transduction by receptors with tyrosine kinase activity. Cell, 61, 203-212.
2. Kolibaba, K.S. & Druker, B.J. (1997). Protein tyrosine kinases and cancer. Biochim. Biophys. Acta, in press.
3. Perlmutter, R.M., Levin S.D., Appleby, M.W., Anderson, S.J. & Alberola-lla, J. (1993). Regulation of lymphocytes by protein phosphorylation. Ann. Rev. Immunol. 11, 451-499.
4. Knighton, D.R., et al., & Sowadski, J.M. (1991). Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate protein kinase. Science 253, 407-414.
5. Knighton, D.R., Zheng, J., Ten Eyck, L.F., Xuong, N.-H., Taylor, S.S. & Sowadski, J.M. (1991). Crystal structure of the catalytic subunit of cAMP-dependent protein kinase. Science 253, 414-420.
6. Taylor, S.S. & Radzio-Andzelm, E. (1994). Three protein kinase structures define a common motif. Structure 2, 345-355.
7. Hanks, K.S., Quinn, A.M. & Hunter, T. (1988). The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241, 42-52.
8. Lawrie, M.A., Noble, E.M., Tunnah, P., Brown, N.R., Johnson, L.N. & Endicott, J.A. (1997). Protein kinase inhibition by staurosporine revealed in details the molecular interaction with CDK2. Nat. Struct. Biol. 4, 796-800.
9. Cox, S., Radzio-Andzelm, E. & Taylor, S.S. (1994). Domain movements in protein kinases Curr. Opin. Struc. Biol. 4, 893-901.
10. Traxler, P.M. (1997). Protein tyrosine kinase inhibitors in cancer treatment. Exp. Opin. Ther. Patents 7, 571-588.
11. Fry, D.W. (1994). Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors. Exp. Opin. Invest. Drugs 3, 577-595.
12. Omura, S., Sasaki, Y., Iwai, Y. & Takeshima, H. (1995). Staurosporine, a potentially important gift from a microorganism. J. Antibiotics 48, 535-548.
13. ++ dependent protein kinase. Biochem. Biophys. Res. Commun. 135, 397-402.
14. Prade, L., Engh, R.A., Girod, A., Kinzel, V., Huber, R. & Bossemeyer, D. (1997). Staurosporine induced conformational changes of protein kinase A catalytic subunit explain inhibitory potential. Structure 5, 1627-1637.
15. Herbert, J.M., Seban, E. & Maffrand, J.P. (1990) Characterization of specific binding sites for [3H] staurosporine on various protein kinases. Biochem. Biophys. Res. Commun. 171, 189-195.
16. 2+/calmodulin-dependent protein kinase II. J. Neurochem. 56, 294-298.
17. Furet, P., et al., & Traxler, P. (1995). Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. J. Comput. Aided Molec. Des. 9, 465-472.
18. Funato, N., et al. & Omura, S. (1994). Absolute configuration of staurosporine by X-ray analysis. Tetrahedron Lett. 35, 1251-1254.
19. +2 adenylyl imidophosphate and inhibitor peptide KPI(5-24). EMBO J. 12, 849-859.
20. Zheng, J-H., et al., & Sowadski, J.M. (1993). Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with a peptide inhibitor. Acta Cryst D 49, 362-365.
21. De Bondt, H.L., Rosenblatt, J., Jancarik, J., Jones, D.H., Morgan, D.O. & Kim, S.H. (1993). Crystal structure of cyclin-dependent kinase 2. Nature 363, 595-602.
22. Engh, R.A., Girod, A., Kinzel, V., Huber, R. & Bossemeyer, D. (1996). Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolonesulfonyl protein kinase Inhibitors H7, H8, and H89. J. Biol. Chem. 271, 26157-26164.
23. Schulze-Gahmen, U., et al., & Kim, S. (1995). Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, Olomoucine and isopentaladenine. Proteins 22, 378-391.
24. De Azevedo, W.F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M. & Kim, S.-H. (1993). Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with Roscovitine. Eur. J. Biochem. 243, 518-526.
25. Hu, H. (1996). Recent discovery and development of selective protein kinase C inhibitors. DDT 1, 438-447.
26. Horton, P.A., Longley, R.E., McConnell, O.J. & Ballas, L.M. (1994). Staurosporine aglycone (K252-c) and arcyriaflavin A from the marine ascidian, Eudistoma sp. Experientia 50, 843-845.
27. Davis, P.D., et al., & Turner, S.E. (1992). Inhibitors of protein kinase C. 1, 2,3-Bisarylmaleimides. J. Med. Chem. 35, 177-184.
28. Trinks, U., et al., & Traxler, P. (1994). Dianilinophthalamides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 37, 1015-1027.
29. De Azevedo, W.F., Jr., Mueller-Dieckmann, H.-J., Schulze-Gahmen, U., Worland, P.J., Sausville, E. & Kim, S.-H. (1996). Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA, 93, 2735-2740.
30. Traxler, P., Furet, P., Mett, H., Buchdunger, E., Meyer, T., & Lydon, N. (1996). 4-(phenylamino)-pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 39, 2285-2292.
31. Traxler, P., et al., & Furet, P. (1997). Use of a pharmacophore model for the design of EGF-Receptor tyrosine kinase inhibitors: 4-(phenylamino)-pyrazolo[3,4-d]pyrimidines. J. Med. Chem., in press.